New Antibiotic for MRSA Infections is Ready for US Clinical Trials

antibiotics mrsa infections destiny 1

Update (15/03/2018): The FDA has granted Fast Track Designation to XF-73, an antibody being developed by Destiny Pharma against post-surgical MRSA infections.


Originally published on 26/02/2018

Destiny Pharma’s antibiotic for post-surgical infections will begin its clinical development after the FDA accepted its Investigational New Drug application. 

Destiny Pharma wants to combat the growing antibiotic resistance crisis by targeting post-surgical infections of methicillin-resistant Staphylococcus aureus (MRSA). The FDA has accepted an investigational new drug application (IND) for Destiny’s MRSA candidate, XF-73, which will allow the company to complete Phase I and finalize the design of a Phase II trial.

XF-73 is a dicationic porphyrin molecule, which is a member of a new class of antibiotics called XF drugs. Interestingly, XF-73 is a nasal gel to reduce the entry of S.aureus through the nose, which represents the source of around a third of all post-surgical infections. The candidate has demonstrated a number of major advantages over current drugs, including their capacity to kill bacteria even when they’re not actively growing; and to attack bacteria within biofilms, a structure that normally protects them from antibiotics.

Destiny launched a £15.3M (€16.7M) IPO on the London Stock Exchange’s AIM market in September and the company’s stock price is up by over 3% this morning. Another company working on new antibiotics is Motif Bio, which is hoping to bring its candidate, Iclaprim, to market after it achieved positive Phase III results.


Image via / Shutterstock

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More